Recently, individual differences that might predict risk for development of dependence and/or risk for relapse have been identified and are being investigated. Of interest to this component are individual differences in """"""""trait-impulsivity."""""""" Findings in animals and humans suggest that a dysfunctional brain dopamine system underlies impulsive traits. Given that the brain dopamine system underlies both impulsivity and reward areas in the brain, it is not surprising that individuals high in trait-impulsivity show different brain regional activity to reward than individuals low in trait-impulsivity. Interestingly, these areas of activation are similar to what has been observed in non-treatment seeking alcoholics (NTSA) following presentation of alcohol cues. We found that aripiprazole, a partial dopamine receptor agonist that putatively """"""""stabilizes"""""""" the dopamine system, reduces drinking and blocks alcohol cue-induced ventral striatal activity in NTSAs, and it does so most clearly in individuals with high trait-impulsivity.
The aim of the current proposal is to replicate and extend this original finding with aripiprazole, in a 2 medication group x 2 trait-impulsivity group prospective experimental design. In addition to studying the interaction of aripiprazole and trait-impulsivity, we also intend to systematically evaluate the role of trait-impulsivity and aripiprazole, per se, as main effects on drinking and craving using our well-validated, natural drinking, brain imaging, and bar-lab alcohol consumption paradigm. Finally, we intend to explore whether functional genetic variants in the brain dopamine system might underlie trait-impulsivity effects and/or aripiprazole response. We will screen about 120 NTSAs and randomize 100 to receive aripiprazole (N=50) (up to 15mg) or matching placebo (N=50) for 8 days. Barratt Impulsiveness Scale (BIS) scores will be used to divide the groups into low versus high trait impulsivity and will be an urn variable to insure equal distribution into both medication groups. After 6-days of natural drinking observation, all subjects will undergo an alcohol cue-induced brain activation (fMRI) paradigm (day-7) and the next day (day-8) will participate in a drinking bar-lab experiment. On day-9, subjects will receive educational counseling about heavy drinking and receive payment for participation.

Public Health Relevance

The ultimate goal of this work is to identify whether a subgroup of alcohol-dependent individuals might respond to aripiprazole. If this human laboratory study indicates that aripiprazole decreases cue-induced brain activation in the ventral striatum and reduces voluntary drinking, a clinical trial of aripiprazole in impulsive treatment-seeking alcoholics would be warranted. This work is very relevant to the goal of improving treatment for alcoholism by matching specific individuals to efficacious medication treatment.

Agency
National Institute of Health (NIH)
Institute
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Type
Specialized Center (P50)
Project #
5P50AA010761-19
Application #
8601280
Study Section
Special Emphasis Panel (ZAA1)
Project Start
2014-01-01
Project End
2015-12-31
Budget Start
2014-01-01
Budget End
2014-12-31
Support Year
19
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Medical University of South Carolina
Department
Type
DUNS #
City
Charleston
State
SC
Country
United States
Zip Code
29403
Dowdle, Logan T; Brown, Truman R; George, Mark S et al. (2018) Single pulse TMS to the DLPFC, compared to a matched sham control, induces a direct, causal increase in caudate, cingulate, and thalamic BOLD signal. Brain Stimul 11:789-796
Zamudio-Bulcock, Paula A; Homanics, Gregg E; Woodward, John J (2018) Loss of Ethanol Inhibition of N-Methyl-D-Aspartate Receptor-Mediated Currents and Plasticity of Cerebellar Synapses in Mice Expressing the GluN1(F639A) Subunit. Alcohol Clin Exp Res 42:698-705
Cannady, Reginald; Rinker, Jennifer A; Nimitvilai, Sudarat et al. (2018) Chronic Alcohol, Intrinsic Excitability, and Potassium Channels: Neuroadaptations and Drinking Behavior. Handb Exp Pharmacol 248:311
Harlan, Benjamin A; Becker, Howard C; Woodward, John J et al. (2018) Opposing actions of CRF-R1 and CB1 receptors on VTA-GABAergic plasticity following chronic exposure to ethanol. Neuropsychopharmacology 43:2064-2074
Hanlon, Colleen A; Dowdle, Logan T; Henderson, J Scott (2018) Modulating Neural Circuits with Transcranial Magnetic Stimulation: Implications for Addiction Treatment Development. Pharmacol Rev 70:661-683
Hanlon, Colleen A; Dowdle, Logan T; Gibson, Nicole B et al. (2018) Cortical substrates of cue-reactivity in multiple substance dependent populations: transdiagnostic relevance of the medial prefrontal cortex. Transl Psychiatry 8:186
Gioia, Dominic A; Xu, Minfu; Wayman, Wesley N et al. (2018) Effects of drugs of abuse on channelrhodopsin-2 function. Neuropharmacology 135:316-327
Anton, Raymond F; Latham, Patricia K; Voronin, Konstantin E et al. (2018) Nicotine-Use/Smoking Is Associated with the Efficacy of Naltrexone in the Treatment of Alcohol Dependence. Alcohol Clin Exp Res 42:751-760
Anderson, Ethan M; Larson, Erin B; Guzman, Daniel et al. (2018) Overexpression of the Histone Dimethyltransferase G9a in Nucleus Accumbens Shell Increases Cocaine Self-Administration, Stress-Induced Reinstatement, and Anxiety. J Neurosci 38:803-813
Osterndorff-Kahanek, Elizabeth A; Tiwari, Gayatri R; Lopez, Marcelo F et al. (2018) Long-term ethanol exposure: Temporal pattern of microRNA expression and associated mRNA gene networks in mouse brain. PLoS One 13:e0190841

Showing the most recent 10 out of 209 publications